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Abstract
Background: Diabetes mellitus (DM) patients surviving myocardial infarction (MI) exhibit a substantially higher
incidence of subsequent heart failure (HF). Neuregulin (NRG)-1 and erythroblastic leukemia viral oncogene homolog
(ErbB) receptors have been shown to play a critical role in maintenance of cardiac function. However, whether
myocardial NRG-1/ErbB is altered during post-MI HF associated with DM remains unknown. The aim of this study
was to determine the impact of type 1 DM on the myocardial NRG-1/ErbB system following MI in relation to residual
left ventricular (LV) function.
Methods: Type 1 DM was induced in rats via administration of streptozotocin (65 mg/kg, i.p.). Control rats were
injected with citrate buffer (vehicle) only. Two weeks after induction of type 1 DM, MI was produced in DM and
non-DM rats by ligation of the left coronary artery. Sham MI rats underwent the same surgical procedure with the
exception that the left coronary artery was not ligated. At 4 weeks after surgery, residual in vivo LV function was
assessed via echocardiography. Myocardial protein expression of NRG-1β, ErbB2 and ErbB4 receptors, and MDM2
(a downstream signaling pathway induced by NRG-1 that has been implicated in cell survival) was assessed in the
remaining, viable LV myocardium by Western blotting. Changes in ErbB receptor localization in the surviving LV
myocardium of diabetic and non-diabetic post-MI rats was determined using immunohistochemistry techniques.
Results: At 4 weeks post-MI, echocardiography revealed that LV fractional shortening (FS) and LV ejection fraction
(EF) were significantly lower in the DM +MI group compared to the MI group (LVFS: 17.9 ± 0.7 vs. 25.2 ± 2.2; LVEF:
35.5 ± 1.4 vs. 47.5 ± 3.5, respectively; P < 0.05), indicating an increased functional severity of HF among the DM +MI
rats. Up-regulation of NRG-1β and ErbB2 protein expression in the MI group was abrogated in the DM + MI group
concurrent with degradation of MDM2, a downstream negative regulator of p53. ErbB2 and ErbB4 receptors
re-localized to cardiac myocyte nuclei in failing type 1 diabetic post-MI hearts.
Conclusions: Type 1 DM prevents compensatory up-regulation of myocardial NRG-1/ErbB after MI coincident with
an increased severity of HF.
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Background
Diabetes mellitus (DM) patients surviving myocardial
infarction (MI) have substantially higher cardiovascular
morbidity and mortality than those without DM [1]. The
poor clinical prognosis of these patients has been linked
primarily to the more frequent development of heart
failure (HF) [2,3]. Despite the higher risk for DM
patients to develop HF after MI, our understanding of
the mechanism(s) by which DM exacerbates the
incidence of this syndrome remains infantile.
Neuregulin (NRG)-1, along with the erythroblastic
leukemia viral oncogene homolog (ErbB) 2, 3, and 4
receptor tyrosine kinases through which NRG-1 ligands
signal, have been shown to play an essential role in
cardiac development [4,5] and maintenance of the adult
heart [6]. In the adult heart, at least 3 different
NRG-1α isoforms and 8 NRG-1β isoforms are expressed,
with the β isoform being 10 to 100 times more bioactive.
Endothelial cells of the endocardium release NRG-1 and
it has been shown to promote the growth and survival
of cardiomyocytes in culture through the activation of
ErbB2 and ErbB4 receptors [7,8]. Cardiac-specific deletion
of ErbB2 and ErbB4 in mice has been reported to result in
the development of dilated cardiomyopathy [6,9]. In vivo,
endothelium-selective deletion of NRG-1 has been
demonstrated to worsen post-ischemic contractile recovery
after coronary artery ligation [10].
Recently, changes in the NRG-1/ErbB system have
been documented to occur in the setting of type 1 DM.
In rats with type 1 diabetic cardiomyopathy, mRNA
expression and phosphorylation of the ErbB2 and ErbB4
receptors as well as NRG-1 protein expression were
observed to be markedly decreased [11]. Administration
of NRG-1 to type 1 diabetic cardiomyopathy rats resulted
in a significant improvement in cardiac function [12].
These findings suggest that alterations in NRG/ErbB
signaling may play a pathophysiological role in the devel-
opment of cardiac dysfunction associated with type 1 DM.
However, studies examining the impact of DM per se on
the myocardial NRG-1/ErbB system in response to MI
remain absent.
Accordingly, the aim of the present study was to
determine whether DM adversely affects myocardial
NRG-1/ErbB after MI and thereby enhances the develop-
ment of HF. Using a rat model of HF due to MI by
coronary ligation in the presence of STZ-induced
DM, a type 1 model, we assessed the protein expression
profiles of NRG-1β, ErbB2 and ErbB4 receptors, MDM2
(a downstream signaling pathway induced by NRG-1 that
has been implicated in cell survival), as well as changes
in ErbB receptor localization in the surviving LV myocar-
dium of diabetic post-MI rats in relation to residual LV
function. We chose to utilize a type 1 DM model even
though the vast majority of acute myocardial infarct
patients are type 2 diabetics for several reasons. First,
the risk of mortality from ischemic heart disease is
exceptionally high in patients with type 1 DM [13].
Second, considering that patients with type 1 DM are
younger at the onset of their disease, they stand to lose
many more life-years from cardiovascular disease, which
includes MI and HF, than do those with type 2 DM [14].
Lastly, published work on DM and the heart has been
related mainly to type 2 DM despite the fact that type 1
DM imparts substantial risk for cardiac disease [15]. As
such, we specifically employed a type 1 DM model in the
present study to directly address the disparity in studies
on cardiovascular disease in type 1 DM.
Methods
Experimental animals
Sprague–Dawley rats were obtained from Harlan (Indian-
apolis, IN). Experiments were performed according to a
protocol approved by the Institutional Animal Care and
Use Committee at Vanderbilt University Medical Center
(Protocol ID#: M/09/322). The investigation conforms to
the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health.
Induction of Type 1 DM
Type 1 DM was induced in male Sprague–Dawley rats
(200–224 g body weight) by administering a single
intraperitoneal injection of STZ (65 mg/kg body wt)
prepared daily in citrate buffer pH 4.5 for maximal
stability. The control vehicle (CV) group was injected
with an equal volume of the vehicle. Development of DM
was confirmed 48 hours later by the presence of glycosuria
(>2000 mg/dl) along with polyuria as described previously
[16]. Two weeks after induction of DM, diabetic and
non-diabetic rats underwent surgical induction of MI.
Induction of MI
Rats were anaesthetized intraperitoneally with Nembutal
(40 mg/kg). Rats were then rapidly intubated and
mechanically ventilated by a constant volume small
animal ventilator (Model 683, Harvard Apparatus). A
left thoracotomy was performed at the fourth intercostal
space and the LAD was ligated at the level immediately
below the bottom of the left atrium by irreversible
tightening of a 6–0 suture loop. The bottom of the
left atrium was used as a demarcation point to ensure
consistent placement of the ligature and resultant repro-
ducibility of similar infarct sizes among the groups of
animals. This demarcation point was also used to avoid
ligation of the LAD too proximally to its origin which
would lead to fatal cardiac arrhythmias. MI was confirmed
by regional cyanosis of the myocardial surface distal to
the suture, accompanied by S-T segment elevation on
the electrocardiogram (ECG). Sham MI (SMI) animals
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underwent the same surgical procedure with the excep-
tion that the LAD was not ligated. Rats were allowed to
recover and then used at 4 weeks post-MI for different
studies.
Assessment of In vivo residual LV function by
echocardiography
Transthoracic echocardiographic images of hearts from
all groups of rats were obtained at 4 weeks post-MI using
an ultra high-resolution ultrasound scanner (Vevo 2100;
VisualSonics) under nembutal anesthesia. For M-mode
recordings, the parasternal short-axis view was used to
image the heart in two dimensions at the level of the
papillary muscles. LV fractional shortening (FS) and
ejection fraction (EF) were recorded along with LV cavity
dimensions (end-diastolic and end-systolic).
Tissue harvest
Following echocardiographic assessment, hearts from all
groups of rats were rapidly excised and perfused with
ice-cold physiological saline and weighed. The atria and
ventricles were dissected and the infarcted (scar) and
non-infarcted regions of the LV was separated, weighed,
and frozen in liquid nitrogen. The non-infarcted LV
tissue was used for all molecular analyses.
Pieces of tissues from the lungs and liver were removed
and weighed. For the determination of dry weight, these
were placed in an oven at 65°C until a constant weight
was reached. Ratios of wet to dry weight were calculated
for both lungs and liver.
Western blot analysis
LV tissue was homogenized in 1X RIPA lysis buffer
(Millipore), supplemented with protease inhibitor cocktail
(Roche). 50 μg of protein was loaded onto a PAGE using
precasted gradient gel 4-12% NuPage gels (Invitrogen).
After electrophoresis, proteins were transferred to an
Immun-Blot PVDF membrane using a Semi-Dry transfer
apparatus. Membranes were blocked using PBST-5%
BSA and then incubated overnight at 4°C with antibodies
directed against ErbB2, ErbB4 and murine double minute
2 (MDM2) (clone F-11, clone C-18, and H-221, respect-
ively) (Santa Cruz). NRG-1β and α-tubulin (Santa Cruz)
were also analyzed by western blot. Secondary horseradish
peroxidase-conjugated antibody (Cell Signaling) was
applied for 1 h at room temperature. Blots were visualized
using the SuperSignal West Pico chemiluminiscent
substrate (Thermo Scientific) and analyzed with NIH
Image J densitometry software.
Immunohistochemistry
LV specimens were embedded in O.C.T. medium
(Tissue-Tek), and 5–10 μM sections were prepared with
a cryotome. Nonspecific binding was blocked with 0.1%
Bovine serum albumin in PBS for 30 min, and coverslips
were incubated overnight with anti-ErbB2 and anti-ErbB4
(Santa Cruz) and antibody against N-Cadherin (Sigma). A
secondary antibody conjugated with FITC and
TXRD-conjugated phalloidin (Molecular Probes) was
added for 1 h. Coverslips were mounted using Vectashield
(Vector laboratories). DAPI (Vector laboratories) was used
according to manufacturer instructions for nuclear
staining. Images were generated with LSM710 confocal
microscope (CIRC, Vanderbilt University).
Measurement of blood glucose
Prior to MI surgery and at the time of sacrifice, blood
samples were collected from the tail vein for the deter-
mination of blood glucose levels using Accutrend Plus
test strips and meter (Roche).
Protein determination and statistical analysis
Protein concentrations of LV tissue samples were deter-
mined using the Modified Lowry Protein Assay Reagent
Kit (Pierce). Data were expressed as the mean ± S.E.M.
Group means were compared by one-way analysis of
variance (ANOVA), and ANOVA followed by Bonferroni’s
test was used to identify differences between multiple
groups. Comparisons between two groups were performed




Mortality following induction of MI was higher among
the DM+MI group compared to the MI group (47% vs.
33%). Blood glucose levels were significantly elevated in
the DM and DM +MI groups of rats compared with the
non-diabetic animal groups (Table 1). Animals in the
DM and DM+MI groups showed significantly less weight
gain as compared to their non-diabetic counterparts
(Table 1). Heart weight was increased in the MI and
DM +MI groups (Table 1). No significant differences in
the weight of myocardial scar caused by the infarction
were observed between MI and DM +MI groups of rats
(Table 1). The wet to dry weight ratios of the lungs was
observed to be elevated only in the DM +MI animals
(Table 1), suggesting that severe HF was present only in
this group.
Type 1 DM exacerbates post-MI HF independent of
adverse remodeling
Echocardiographic studies revealed differences in residual
LV function between MI and DM+MI groups of rats.
Representative echocardiograms obtained from a sham
MI, MI and DM+MI rat are shown in Figure 1. Echocar-
diographic data are summarized in Table 2. LVFS and
LVEF were significantly lower in the DM+MI group
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compared to the MI group, indicating an increased
functional severity of HF in the diabetic post-MI group.
Although a statistically significant reduction in LVEF and
LVFS was also observed in the DM group without MI, the
magnitudes of such decreases were significantly less as
compared to the DM+MI group. Heart rate was signifi-
cantly lower in the DM and DM+MI groups (Table 2).
As shown in Table 2, MI and DM+MI groups of rats
had a significantly larger LV chamber size as compared to
the sham MI group as indicated by significant increases in
LVIDd and LVIDs. However, no differences in LVIDd and
LVIDs were observed between the MI and DM+MI
groups themselves. This observation is consistent with the
findings from the Survival and Ventricular Enlargement
(SAVE) echocardiographic substudy which demonstrated
that after MI, diabetes is not associated with greater
ventricular enlargement [17]. Although an increase in
LVIDd and LVIDs was observed in DM rats in the absence
of MI, the extent of such increases were significantly less
pronounced compared with the DM+MI group of rats.
Up-regulation of NRG-1β in post-MI heart is abolished by
the presence of type 1 DM
Myocardial NRG-1β protein expression showed differences
between the MI and DM+MI groups of rats (Figure 2). A
96% and 63% increase in the protein expression of the
115 kDa and 185 kDa fragments of NRG-1β, respectively,
was observed in the MI group compared to the sham MI
rats (Figuire 2B + 2C). In contrast, there was a 44% and
39% decrease in the expression of the 115 kDa and
185 kDa fragments of NRG-1β, respectively, in the DM+
MI group vs. the MI group (Figure 2B + 2C). Interestingly,
in the DM group without MI, a significant decrease in the
expression of only the 115 kDa fragment of NRG-1β was
observed compared to the CV group (Figure 2B). We also
observed that the 115 kDa NRG-1β fragment was
down-regulated with sham surgery.
Up-regulation of myocardial ErbB2 after MI is suppressed
by concurrent type 1 DM
Myocardial ErbB2 and ErbB4 receptor protein expression
was analyzed in all groups of rats (Figure 3). Compared to
the sham MI group, a 21% increase in myocardial ErbB2
protein expression was observed in the MI group
(Figure 3B) while no differences in protein expression was
observed with respect to ErbB4 (Figure 3C). However,
in the DM +MI group, a 67% decrease in the protein
expression level of the ErbB2 receptor was observed
compared to the MI group (Figure 3B). Although a
decrease in the protein expression level of the ErbB4
receptor was also observed in the DM+MI group
compared to the MI group (Figure 3C), this reduction did
not reach statistical significance. The expression levels of
ErbB2, but not ErbB4, were significantly decreased in DM
hearts without MI when compared with the CV group
(Figure 3B).
MDM2 is down-regulated in the failing type 1 diabetic
post-infarction heart in parallel with increased MDM2
degradation
Myocardial MDM2 protein expression was analyzed in
all groups of rats (Figure 4). Cardiac expression of
MDM2 was significantly decreased in DM+MI rats vs.
sham MI and MI groups of rats (33% and 31% decrease,
respectively) whereas such down-regulation of MDM2
was not observed in non-diabetic MI rats (Figure 4B).
The reduction in MDM2 protein expression in the
DM+MI group was associated with evidence of MDM2
degradation (Figure 4A). Similar results were observed
in DM rats without MI. MDM2 expression levels were
also observed to be lower with sham surgery.
Localization of ErbB receptors is disrupted in the type 1
diabetic post-MI heart with advanced HF
We examined the cellular localization of ErbB2 and
ErbB4 in heart tissue by immunostaining. In the control
vehicle heart, ErbB2 and ErbB4 were localized primarily
in the cellular membrane of myocytes including the
intercalated disk (Figure 5D + Figure 6D, respectively).
Cellular membrane staining for ErbB2 were less clear in
the DM heart (i.e. outline of myocyte) (Figure 5E) which
became more diffuse in the DM+MI heart (Figure 5F).
The DM and DM+MI heart demonstrated a prominent
peri-nuclear localization of ErbB2 (Figure 5E + 5F,
Table 1 Animal characteristics at 4 weeks post-MI
Parameter CV DM Sham MI MI DM +MI
Body Weight, g 365 ± 10.6 225 ± 11.6* 356 ± 7.0 376 ± 9.4# 227 ± 7.7*†‡
Blood Glucose, mg/dl 152 ± 6.1 547 ± 20.2* 142 ± 7.3 163 ± 5.2# 549 ± 13.9*†‡
Total Heart Weight, g 1.2 ± 0.03 0.9 ± 0.08* 1.3 ± 0.03 1.5 ±0.05†# 1.3 ± 0.06#‡
Scar Weight, g ND ND ND 0.20 ±0.03 0.19 ± 0.02
Lung Wet/Dry 4.8 ± 0.03 4.8 ± 0.08 5.1 ± 0.11 5.0 ± 0.09 5.3 ± 0.08*#‡
Liver Wet/Dry 3.3 ± 0.12 3.0 ± 0.11 3.2 ± 0.05 3.1 ± 0.12 3.3 ± 0.04
Values are mean ± standard error of the mean of four to six animals. ND: not detectable. CV, control vehicle; DM, diabetes mellitus; Sham MI, sham myocardial
infarction, MI, myocardial infarction; DM +MI, diabetes mellitus + myocardial infarction. *P < 0.05 vs. CV; †P < 0.05 vs. Sham MI; #P < 0.05 vs. DM; ‡P < 0.05 vs. MI.
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respectively). Nuclear ErbB4 staining was apparent in
some myocyte nuclei from DM rat hearts (Figure 6E).
However, in the DM+MI heart, more prominent
nuclear ErbB4 staining was observed (Figure 6F).
Discussion
Little is known about perturbations in biological processes
that take place in the diabetic heart following MI. The
major novel findings of the present study are: (1) up-
regulation of myocardial NRG-1β protein expression
following MI is abrogated by the concomitant presence
of type 1 DM; (2) up-regulation of myocardial ErbB2
protein expression following MI is abrogated by the
concomitant presence of type 1 DM; (3) degradation
and decreased protein expression of MDM2 occurs in
type 1 diabetic post-MI hearts; (4) ErbB2 and ErbB4
re-localize to the nucleus from the intercalated disk
in cardiac myocytes of failing type 1 diabetic post-MI
hearts; and (5) these alterations in the myocardial
NRG-1β/ErbB pathway in the type 1 diabetic post-
infarction heart are associated with an increased functional
severity of HF. These findings shed new light on the
underlying mechanisms that contribute to the impaired
response to infarction in diabetic hearts. Furthermore, our
data support the concept that augmentation of myocardial
NRG-1β/ErbB is an important cardioprotective adaptation
to MI that is lost in the presence of type 1 DM.
Numerous studies have demonstrated the cardio-
protective role of the NRG-1/ErbB signaling pathway.
Ischemia-reperfusion injury is associated with activation
of NRG-1β/ErbB4 signaling that mediates recovery [18].
NRG-1/ErbB signaling is also activated during the early
stages of HF [19], similar to what we observed in the post-
MI heart. Reduced NRG-1/ErbB signaling is associated
with impaired myocyte resistance to the cytotoxic effects
of neurohormonal stimuli such as β1-adrenergic receptor
activation [20]. The demonstration in the present study
that type 1 DM prevents up-regulation of myocardial
NRG-1β/ErbB expression in response to MI concomitant
with an increased severity of HF further illustrates that the
NRG-1β/ErbB system in the heart appears to be a local
cardioprotective signaling system. Moreover, failure of
adaptive tuning of myocardial NRG-1β/ErbB to MI in the
presence of DM may explain, in part, how the diabetic
post-MI heart is rendered more prone to accelerated HF.
In the present study, we found that STZ-diabetic rats
without MI exhibited reduced myocardial expression of
the 115 kDa fragment of NRG-1β and ErbB2 receptor.
This is consistent with a recent report showing
down-regulation of ErbB receptor mRNA expression
and NRG-1 protein expression in LV myocardium of
STZ-diabetic rats [11]. Collectively, these observations
point to DM per se as the adverse factor and suggest that
the suppression of the NRG-1β/ErbB pathway induced by
STZ-diabetes precludes harnessing this system as a
compensatory mechanism to help in recovery of myo-
cardial function after superimposition of cardiac injury
involving MI. One question that arises from these findings
is: How does DM down-regulate myocardial NRG-1/ErbB
expression? In this regard, NRG-1 mRNA and protein ex-
pression are known to be down-regulated by angiotensin
II [21]. In light of the fact that the activity of the Renin-
Angiotensin-Aldosterone System (RAAS) is increased in
DM, over-activation of RAAS may serve as a potential
mechanism by which DM suppresses NRG-1 expression.
Physiological metabolic stress of β-adrenergic receptor
stimulation by norepinephrine causes ErbB2 degradation
[20]. Increased catecholamine levels in cardiac tissue are a







Figure 1 Representative echocardiographic images of diabetic
and non-diabetic rat hearts at 4 weeks after MI. Images consist
of 2-dimensional echocardiography at parasternal short-axis plane
(top portion) and M-mode short axis of LV (bottom portion). (A):
Sham MI; (B): MI; (C): DM +MI.
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potential mechanism underlying reduced ErbB receptor
expression.
Having found that ErbB2 and ErbB4 protein expression
was down-regulated in type 1 diabetic hearts with
advanced post-MI HF, we also looked at their localization
in cardiomyocytes. Our results demonstrate that ErbB2 lo-
calizes to the peri-nuclear area and ErbB4 localizes to the
nucleus in cardiac myocytes of failing type 1 diabetic post-
MI hearts, thereby confirming our Western blot analysis.
Previous studies have demonstrated that the increased
localization of ErbB4 to the nucleus in adult rat ven-
tricular myocytes may be an indicator of cell stress
response [23], a finding that has also been observed in
other receptor tyrosine kinases [24]. Whether nuclear
localization of ErbB receptors affects their availability and/
or ability to bind NRG-1 ligands and thereby contribute to
the obliteration of compensatory NRG-1/ErbB signaling
in the diabetic heart after MI is equally important from a
therapeutic standpoint and warrants further investigation.
MDM2 is activated by ErbB2 signaling and under
normal circumstances is the principal negative regulator
of p53 via ubiquitination and subsequent degradation
[25] (Figure 7A). Since we found that ErbB2 protein
expression was down-regulated in type 1 diabetic hearts
with advanced post-MI HF, we examined whether
MDM2 was also suppressed. Our data shows for the first
time that the deleterious effects of type 1 DM on the
myocardial NRG-1/ErbB pathway extend downstream of
the ErbB2 receptor as evidenced by degradation and
decreased expression of MDM2 in type 1 diabetic hearts
with and without MI. This result may be of particularly
important significance in that it may help to further our
Figure 2 Myocardial NRG-1β protein expression in MI and DM+MI groups of rats. (A): Representative Western blots for 115 kDa and
185 kDa fragments of NRG-1β, (B): Densitometric analysis of the immunoreactivity of the 115 kDa fragment of NRG-1β, (C): Densitometric analysis
of the immunoreactivity of the 185 kDa fragment of NRG-1β. In all samples, the densitometric measurements of NRG-1β immunoreactivity were
normalized to α-tubulin expression. *P < .01.
Table 2 Echocardiographic assessment of In Vivo residual LV function at 4 weeks post-MI
Parameter CV DM Sham MI MI DM +MI
LVFS,% 43.4 ± 1.9 34.3 ± 1.1* 40.4 ± 1.0 25.2 ± 2.2†# 17.9 ± 0.7*†#‡
LVEF,% 73.3 ± 2.3 61.5 ± 1.5* 69.5 ± 1.2 47.5 ± 3.5†# 35.5 ± 1.4*†#‡
LVIDd, mm 6.3 ± 0.22 7.7 ± 0.20* 6.6 ± 0.24 9.3 ± 0.55†# 9.2 ± 0.67*†
LVIDs, mm 3.6 ± 0.23 5.1 ± 0.17* 4.2 ± 0.19 7.0 ± 0.55†# 7.8 ± 0.37*†#
Heart Rate, bpm 350 ± 23.5 241 ± 9.0* 376 ± 16.5 361 ± 11.1# 299 ± 9.3†#‡
LVFS, left ventricular fractional shortening; LVEF, left ventricular ejection fraction; LVIDd, left ventricular internal dimension, diastolic; LVIDs, left ventricular internal
dimension, systolic. Values are mean ± standard error of the mean of four to six animals. *P < 0.05 vs. CV; †P < 0.05 vs. Sham MI; #P < 0.05 vs. DM; ‡P < 0.05 vs. MI.
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understanding of how DM induces myocardial apoptotic
cell death, a key initiating factor for the development of
diabetic cardiomyopathy. Although myocardial apoptosis
was not measured in cardiac tissue sections in the
present study, in cardiac myocytes, hyperglycemia has
been documented to activate p53 leading to myocyte cell
death [26]. In vivo, cardiac expressions of p53 have been
observed to be markedly increased in STZ-diabetic
animals [27,28] resultantly promoting enhanced myocyte
apoptosis [28]. Together, these observations raise the
Figure 4 Myocardial protein expression of MDM2 in MI and DM+MI rats. (A): Representative Western blot for MDM2, (B): Densitometric
analysis of MDM2 immunoreactivity. Arrow shows MDM2 degradation product. In all samples, the densitometric measurement of MDM2
immunoreactivity was normalized to α-tubulin expression. **P = .003; ***P < .0001.
Figure 3 Myocardial ErbB2 and ErbB4 receptor protein expression in MI and DM+MI rats. (A): Representative Western blots for ErbB2 and
ErbB4, (B): Densitometric analysis of ErbB2 receptor immunoreactivity, (C): Densitometric analysis of ErbB4 receptor immunoreactivity. In all
samples, the densitometric measurements of ErbB2 and ErbB4 immunoreactivity were normalized to α-tubulin expression. *P = .02; ***P < .0001.
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interesting possibility that the enhanced cardiac apoptotic
cell death imposed by DM may stem from its actions on
the MDM2-p53 pathway whereby DM represses the
inhibitory effects that MDM2 typically has on p53. This
proposed molecular mechanism of action by DM is
illustrated in Figure 7B. Further studies, such as MDM2
over-expression, will be needed to confirm whether DM
may additionally execute its deleterious effects on the
myocardium via alteration of the MDM2/p53 axis.
Derangements in fatty acid metabolism inherent to DM
may be responsible for and linked to diabetes-induced
changes in myocardial NRG-1/ErbB signaling. Fatty acid
accumulation increases cardiac p53 expression in
association with cardiac dysfunction in DM [27]. Marked
up-regulation of several enzymes involved in fatty acid
metabolism occurs in the hearts of STZ-diabetic rats [16].
In vitro, it is interesting that treatment of neonatal rat
cardiac myocytes with the saturated fatty acid palmitate
disrupts NRG-1β activation of the PI3-kinase/Akt pathway
leading to an increase in p53 expression concurrent with
degradation of MDM2 [29]. The phosphorylation of Akt
has been reported to be markedly decreased in the
hearts of diabetic animals [30,31]. Taken together, these
observations raise the intriguing possibility that
diabetes-induced increases in the levels of circulating
fatty acids may contribute to alterations in myocardial
NRG-1β/ErbB signaling and biology.
The significantly lower HR observed in the STZ-diabetic
groups of rats is consistent with our previous observations
[16,32] as well as prior reports in the literature [33-37]
and may be due to cardiac autonomic neuropathy [33,34].
Although reductions in heart rate are routinely associated
with cardiac depression, studies undertaking functional
comparison at comparable heart rates via pacing in
STZ-diabetic rats have reported similar alterations in
myocardial contractility despite correcting for heart rate
[38,39]. Therefore, the LV systolic dysfunction observed in
the DM and DM+MI groups cannot merely be the result
of the much reduced heart rate and instead points to
greater impairment of myocardial contractile function.
The tendency of clinical trials to focus on cardiovascu-
lar disease in type 2 DM (as opposed to type 1 DM) in
Figure 5 Immunolocalization of ErbB2 receptor in failing diabetic post-MI rat heart. Cross-sections of rat heart tissue (A-F) were
immunostained for ErbB2 (red), N-Cadherin (green), and DAPI (blue), visualized by confocal microscopy. Controls lacking primary anti-ErbB2
antibody showed minimal background staining (data not shown). Bar represents 20 μM. Immunolocalization images representative of 5–6 animals
per group.
Odiete et al. Cardiovascular Diabetology 2013, 12:52 Page 8 of 12
http://www.cardiab.com/content/12/1/52
spite of the fact that the age-adjusted relative risk for
cardiovascular disease in type 1 DM far exceeds that of
type 2 DM has resulted in an under-appreciated link
between type 1 DM and cardiac disease [15]. As such, in
the present study, we aimed to bridge this gap by
employing un-treated STZ-induced diabetes, a well-
established model of type 1 DM that closely recapitu-
lates uncontrolled hyperglycemia due to absolute insulin
deficiency. While possible confounding effects of STZ
administration have been suggested to occur acutely, the
half-life of the drug is ~15 minutes, and it is cleared
from the organs within 4 hours [40]. Given that the data
reported in the present study was obtained at 6 weeks
after STZ injection, the results reported herein are likely
related to the development of diabetes. Furthermore, the
reversal of accompanying mechanical changes in cardiac
function induced by STZ with insulin [41,42] renders
the possibility that the abnormalities observed among
the diabetic animals in the present study being due to
drug toxicity, rather than the diabetic condition itself,
extremely unlikely.
Study limitations
First, our data do not provide direct proof of a cause-
and-effect relationship between the impairment of myo-
cardial NRG-1β/ErbB up-regulation after MI and the
exacerbation of LV failure by type 1 DM. However, in a re-
cent study, administration of recombinant human NRG-1
(rhNRG-1) to STZ-induced diabetic cardiomyopathy rats
rescued the depressed cardiac function [12] suggesting
that derangements in NRG-1/ErbB may play a causal role
in the decreased cardiac function brought about by DM.
Further studies examining whether these same effects of
NRG therapy can be recapitulated in diabetic hearts with
co-existing ischemic injury are required to answer this
crucial question that was not examined in the present
study. Second, the results of the present study do not
delineate how MDM2 is being degraded. While beyond
the scope of this study, future experiments are needed to
fully elucidate the detailed mechanisms by which DM
induces degradation of MDM2 in the heart. Lastly, the
115 kDa NRG-1β fragment and MDM2 were observed to
be down-regulated with sham surgery. NRG and MDM2
Figure 6 Immunolocalization of ErbB4 receptor in failing diabetic post-MI rat heart. Cross-sections of rat heart tissue (A-F) were immunostained
for ErbB4 (red), N-Cadherin (green), and DAPI (blue), visualized by confocal microscopy. Controls lacking primary anti-ErbB4 antibody showed minimal
background staining (data not shown). Bar represents 20 μM. Immunolocalization images representative of 5–6 animals per group.
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expression levels may be negatively influenced by the
inflammatory microenvironment [43,44] which could
explain this result. Nonetheless, since the sham surgery
group served as a control for our MI and DM+MI
groups, the differences in NRG-1β and MDM2 protein
expression found in each of the MI and DM+MI groups
cannot be attributed simply to inflammatory responses
invoked by the thoracotomy itself.
Figure 7 Schematic of the NRG-1/ErbB pathway in the normal and diabetic heart. (A) Schematic of the NRG-1/ErbB pathway in the normal
heart. NRG-1/ErbB activates a number of downstream signaling cascades, such as PI3-kinase, AKT, and MDM2. Activation of MDM2 causes
ubiquitination and resultant degradation of p53 resulting in the latency of p53 action. (B) Proposed molecular mechanism of action by which
type 1 DM suppresses the myocardial NRG-1/ErbB pathway. Degradation and decreased expression of MDM2 induced by type 1 DM may
appreciably reduce the inhibitory effects that MDM2 typically has on p53 and as such may represent a potential molecular mechanism for
diabetes-induced cardiac cell death and associated cardiomyopathy.
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Conclusions
Our results suggest that loss of compensatory up-
regulation of myocardial NRG-1β/ErbB coupled with
disruption of ErbB receptor localization may be responsible,
at least in part, for the greater incidence and severity of
HF in post-MI patients with co-existing DM. In addition,
our finding of degradation and decreased expression of
MDM2 in failing type 1 diabetic infarcted hearts
implicates this downstream ErbB2 receptor-associated
pathway as part of the molecular pathophysiology of
aggravated HF in the type 1 diabetic post-infarction heart.
Taken together, these observations provide innovative and
valuable mechanistic insights into the diabetes-related
deficit in response to MI. Approaches aimed at restoring
the myocardial NRG-1/ErbB pathway in the diabetic
post-MI heart may prove to be beneficial in preventing
and/or ameliorating the subsequent development of HF.
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